MAIA microperimetry
Guangzhou, Guangdong, 510000, China
NCT Number: NCT05904444
Patients who develop macular diseases have several clinical complications,such as central vision loss, the central scotoma of the visual field, the decrease of reading speed and fixation stability. At present, there is still no satisfactory effect in the prevention and treatment of advanced macular disease. A new rehabitation strategy named microperimetric biofeedback training has been shown to be effective in improving patients' visual appearance, but there is no consensus regarding the optimal methodology and standard of practice. Therefore, we designed a prospective clinical study to verify the effectiveness of MBFT and to determine an optimal plan.
Looking for future studies?
Notify Me12 year–80 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510000, China
The present study aimed to investigate the effects of training frequency and number of training sessions on the visual outcomes of patients with various macular diseases. A total of 15 training sessions were conducted on two distinct frequencies, namely once a day and once every other day. Baseline measurements included fixation stability, reading speed, and best corrected visual acuity (BCVA) were obtained and followed up after the 5, 10, and 15 training sessions. By comparing the changes in these visual function parameters across different stages of training, the study aimed to identify and analyze the underlying patterns and rules governing the training process. Ultimately, the results of this study could serve as a valuable reference for standardizing the use of MBFT in clinical practice.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
participants who (1) were diagnosed with macular disease and had a BCVA poorer than 20/60; (2) with stable fundus lesion in fundus examinations; (3)with education level beyond the third grade; (4)had no other effective treatment; and (5)were willing to improve visual quality.
Exclusion criteria
who (1) received ocular treatments in the preceding 3 months, (2) with active fundus lesions like inflammation, bleeding, exudation, edema, (3) with obvious opacity of the refractive media such as keratopathy, severe cataract, or severe vitreous opacity, (4) were unable to attend scheduled follow-up appointments.
Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
Time frame: 5 minutes
An index for evaluating macular disease, defined as the accuracy of a patient's gaze at a target over a period of time.
Time frame: 2 minutes
The most important indicator of visual function, refers to the function of distinguishing objects in the state of refractive correction.
Time frame: 3 minutes
One of the indicators for evaluating reading ability, which refers to the number of words within a certain period of time when reading
Time frame: 10 minutes
Questionnaires were used to determine the influence of eye symptoms and visual impairment on daily life attributed to the limitation of patients' social function and activities.
Aier Eye Hospital, Guangzhou
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03011541
Abnormalities, Multiple, Age-Related Macular Degeneration
Westport, Connecticut, United States
View Trial DetailsNCT07577219
Blindness, Blindness, Cortical
Boston, Massachusetts, United States
View Trial DetailsNCT06805474
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Dallas, Texas, United States
View Trial DetailsNCT00060749
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Erythrokeratodermia with ataxia
Bethesda, Maryland, United States
View Trial Details